TSH Correlation between thyroid-stimulating hormone (TSH) in Middle-aged with major beta-thalassemia
One of the most common endocrine glands problems in cases of beta-thalassemia major are hypothyroidism, and the objective of this study is to assess the status of thyroid hormone stimulating (TSH) has thalassemia major patients ,Thalassemia is an autosomal genetic disease leading to anemia and remains one of the major health problems in Southeast Asia and other parts of the world where malaria is or has been endemic, Beta-thalassemia major is a common inherited hematological disorder in Asia..samples were collected from Iraqi individuals who attended to the to Thalassemia Center in Ibn Al- Baladi Hospital . Approximately 5 ml of human blood(Healthy and Patients) was collected from each individuals and transfer red into sterilized test tubes . TSH group contains ready to use reagents that have been previously distributed in sealed strips. All steps have been made automatically by testing the immune system diagnostic testing tool (VIDAS) instrument. Fifteen patients control (29 females and 21 males) in this study. The median age was 30-28 years.and 151 patients.number of sample there use in this study were (51 B- thalassaemia,50Hb anima and 50 control ).all sample tested by Serum ferritin levels were obtained through automated quantitative test for use vidase.
The limits for normal ferritin levels 138-321 in man and 27.15-102 ng/ul in woman . 51 cases of B- thalassaemia, The mean serum ferritin levels in cases of B- thalassaemia were 9542 + 782 ng/ml while were Serum Ferritin Levels in control sample 138+323in male and 28-108ng/ml in female. Then conducted this test on patients Hbaneima Where Levels of Serum Ferritin in this patients was 1+80 ng/ml. Age of all patients in this study were 3day-9year .the patients of B- thalassaemia were 1-6 year and p-value was(0.236951)while the age of patient Hbaneima was 1-5 year and p-value was (0.112275).
and Some of the thyroid gland parameters in patients in the ranges of abnormal compared with controls, except for some cases that have levels (TSH) are normal.Exacerbation of thyroid function was observed in 60% of thalassemia patients who studied in middle age
2- Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD(2004). Del Vecchio GC, et al. Survival and complications in patients with Haematologica;89(10):1187-93.
3-Telfer PT, Warburton F, Christou S, Hadjigavriel M, Sitarou M, Kolnagou A. (2009).Improved survival in thalassemia major patients on switching, from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone.Haematologica, Vol. 94(12), pp. 1777-8.
4-De Sanctis V, Roos M, Gasser T,Fortini M, Raiola G, Galati MC.(2006).Italian Working Group on Endocrine Complications in Non-Endocrine Diseases.Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia. J PediatrEndocrinolMetab, Vol.19, pp. 471-80.
5. Haghshenas M, Zamani J. Talasemia(2007). 1st ed. Shiraz: Shiraz University of Medical Sciences publication; pp: 1-2. [In persion].
6. Srivatsa A, Arivatsa A. (2005).Assessment of adrenal endocrine function in Asian thalassemics. Indian Pediatr;42(1):31–5.
7-William, S. and Messer J. (2000).Thyroid hormones.Endocrinology &Metabolism.11(4):123-128.
8-Boelaert, K. and Franklyn A. (2005).Thyroid hormone in health and disease. J. of Endo.187:1-15.
9- Malik S, Syed S, Ahmed N. (2009).Complications in transfusion-dependent patients with betathalassemia major: a review. Pak J Med Sci;25(4):678-82.
10. Shamshirsaz AA, Bekheirnia MR, Kamgar M, et al.(2003) Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter study in Tehran. BMC Endocr Disord;3(1):23-34.
11. Malik SA, Syed S, Ahmed N. (2010).Frequency of hypothyroidism in patients of beta-thalassemia. Pak I Med Assoc;60(1):17-29.
12-De Sanctis V, Eleftheriou A, Malaventura C. (2004) Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF). PediatrEndocrinol Rev, Suppl 2, pp. 249-55.
13-Delvecchio, M.; Cavallo, L. (2010). Growth and endocrine function in thalassemia major in childhood and adolescence. J. Endocrinol. Invest, Vol.33, pp. 61-68.
14-Landau H, Matoth I, Landau-Cordova Z, Goldfarb A, Rachmilewitz EA, Glaser B. (1993). Cross-sectional and longitudinal study of the pituitary-thyroid axis in patients with thalassaemia major, ClinEndocrinol (Oxf), Vol.38(1), pp. 55-61.
15-Wondeisford, F.E., Magner, J.A. and Weintraub, B.D.(1996).Chemistry and biosynthesis of thyrotropin in brave man .7th ed. Philadelphia Lippincott-Raven. 190-207.
17-Botella-Carretero JI, Alvarez-Blasco F, Sancho J, Escobar-Morreale HF.(2006).. Effects of thyroid hormones on serum levels of adipokines as studied in patients with differentiated thyroid carcinoma during thyroxine withdrawal. Thyroid.16(4):397-402.
18. Agarwal MB.(2009). Advances in management of Thalassemia. Indian J pediatr; 76: 177-84.
19. Hershko C.(2002).Role of iron chelation therapy in thalassemia major. Turk J Haematol.19: 121-6.
20. Hoffbrand A, Cohen A, Hershko C. Role .(2003).of deferiprone in chelation therapy for transfusional iron overload. Blood .102: 17-24.
* Forensic DNA Research and Training Center/ AL- Nahrain University.(corresponding author)/ email@example.com
Copyright (c) 2019 GPH - International Journal of Biological Science →
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Author(s) and co-author(s) jointly and severally represent and warrant that the Article is original with the author(s) and does not infringe any copyright or violate any other right of any third parties, and that the Article has not been published elsewhere. Author(s) agree to the terms that the GPH Journal will have the full right to remove the published article on any misconduct found in the published article.